Fernando F Lopez-Calderon
Overview
Explore the profile of Fernando F Lopez-Calderon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alburquerque-Gonzalez B, Lopez-Calderon F, Lopez-Abellan M, Esteban-Gil A, Garcia-Solano J, Conesa-Zamora P
Int J Mol Sci
. 2020 Mar;
21(6).
PMID: 32183342
Serrated adenocarcinoma (SAC) is a tumor recognized by the WHO as a histological subtype accounting for around 9% of colorectal carcinomas. Compared to conventional carcinomas, SACs are characterized by a...
2.
Alburquerque-Gonzalez B, Bernabe-Garcia M, Montoro-Garcia S, Bernabe-Garcia A, Rodrigues P, Ruiz Sanz J, et al.
Exp Mol Med
. 2020 Feb;
52(2):281-292.
PMID: 32080340
Serrated adenocarcinoma (SAC) is more invasive, has worse outcomes than conventional colorectal carcinoma (CRC), and is characterized by frequent resistance to anti-epidermal growth factor receptor (EGFR) and overexpression of fascin1,...
3.
Segovia C, Jose-Eneriz E, Munera-Maravilla E, Martinez-Fernandez M, Garate L, Miranda E, et al.
Nat Med
. 2019 Jul;
25(7):1073-1081.
PMID: 31270502
Bladder cancer is lethal in its advanced, muscle-invasive phase with very limited therapeutic advances. Recent molecular characterization has defined new (epi)genetic drivers and potential targets for bladder cancer. The immune...
4.
Segovia C, Martinez-Fernandez M, Duenas M, Rubio C, Lopez-Calderon F, Costa C, et al.
Oncotarget
. 2017 Jan;
8(6):10531-10542.
PMID: 28060766
The high rates of tumor recurrence and progression represent a major clinical problem in non-muscle invasive bladder cancer. Previous data showed that EZH2-dependent signaling mediates these processes, whereas the frequent...
5.
Martinez-Fernandez M, Rubio C, Segovia C, Lopez-Calderon F, Duenas M, Paramio J
Int J Mol Sci
. 2015 Nov;
16(11):27107-32.
PMID: 26580594
Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies aimed to describe the genomic landscape of BC have underscored the relevance of epigenetic alterations in the...
6.
Martinez-Fernandez M, Duenas M, Feber A, Segovia C, Garcia-Escudero R, Rubio C, et al.
Oncotarget
. 2015 Oct;
6(39):42258-75.
PMID: 26517683
Bladder cancer (BC) is a highly prevalent disease, ranking fifth in the most common cancers worldwide. Various miRNAs have recently emerged as potential prognostic biomarkers in cancer. The miR-200 family,...
7.
Martinez-Fernandez M, Feber A, Duenas M, Segovia C, Rubio C, Fernandez M, et al.
Clin Epigenetics
. 2015 Oct;
7:109.
PMID: 26457124
Background: Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression regulation, being involved in diverse epigenetic processes. They are aberrantly expressed in various tumors, but...
8.
Bornachea O, Lopez-Calderon F, Duenas M, Segrelles C, Lorz C, Suarez-Cabrera C, et al.
Oncotarget
. 2015 Jul;
6(27):24230-45.
PMID: 26203771
The TP63 gene codes for two major isoform types, TAp63 and ΔNp63, with probable opposite roles in tumorigenesis. The ΔNp63α protein is frequently amplified and overexpressed in different epithelial tumors....